-transparent.png){kind=logo}
The cutaneous application of antiviral agents was studied by iontophoresis, a process that increases penetration of most drugs 20- to 60-fold. Twenty-seven subjects with vesicular orolabial herpes were treated one time in a double-blind, placebo-controlled clinical study: nine received vidarabine monophosphate (ara-AMP), nine received acyclovir (ACV), and nine received NaCl. Ara-AMP-treated lesions yielded lower titers of virus after 24 hr compared with lesions treated with NaCl or ACV (P less than .05). Ara-AMP significantly decreased the duration of shedding of virus (P less than .05) and time to dry crust (P less than .05) compared with the other two agents. There was a trend toward decreased healing time after ara-AMP treatment.
L P Gangarosa, and
J M Hill, and
B L Thompson, and
C Leggett, and
J P Rissing
March 1983,
The New England journal of medicine,
L P Gangarosa, and
J M Hill, and
B L Thompson, and
C Leggett, and
J P Rissing
May 1985,
Canadian Medical Association journal,
L P Gangarosa, and
J M Hill, and
B L Thompson, and
C Leggett, and
J P Rissing
February 1979,
The Medical letter on drugs and therapeutics,
L P Gangarosa, and
J M Hill, and
B L Thompson, and
C Leggett, and
J P Rissing
May 1979,
Lancet (London, England),
L P Gangarosa, and
J M Hill, and
B L Thompson, and
C Leggett, and
J P Rissing
January 1978,
FDA drug bulletin,
L P Gangarosa, and
J M Hill, and
B L Thompson, and
C Leggett, and
J P Rissing
February 1985,
Canadian Medical Association journal,
L P Gangarosa, and
J M Hill, and
B L Thompson, and
C Leggett, and
J P Rissing
May 1981,
The New Zealand medical journal,
L P Gangarosa, and
J M Hill, and
B L Thompson, and
C Leggett, and
J P Rissing
January 1982,
Journal of neurology, neurosurgery, and psychiatry,
L P Gangarosa, and
J M Hill, and
B L Thompson, and
C Leggett, and
J P Rissing
May 1976,
American journal of ophthalmology,
L P Gangarosa, and
J M Hill, and
B L Thompson, and
C Leggett, and
J P Rissing
March 1977,
Annals of the New York Academy of Sciences,
